Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

PharmaCyte Biotech (pmcb)

Total paid for Promotions this month: $0
E-mails this Month: 1
Estimated Volume Generated: $0
Research Report on pmcb: Click to see
* The information presented is based on information for Jun , 2016

Play PMCB before the weekend Feb 13, 2015 09:15

  PMCB Reaching For A Turning Point Good Morning!   It’s been a jam-packed week of alert action and I’m starting to think it’s good that I saved PharmaCyte Biotech Inc. (PMCB) for last.   PMCB combines just about all the points that made my recent alerts such no-nonsense plays: simple story, low PPS, technical lines pointing up.   But with PMCB, ...read more
Promoter: StockRoach.com Paying Party: Action Media Holdings
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $4,000 UNKNOWN
Max Profit: 2.84 % Gain at close: Pending
   February 12, 2015 Volume XVIII, Issue 5   OTC Journal Newsletter   PharmaCyte Biotech (OTCQB: PMCB) Shares Surging on Potential Diabetes Therapy On January 30th PharmaCyte Biotech (PMCB) traded to a 13 month low of $.095, but has since rebounded 56%, finding its way back to about the $.15 level. Risk oriented investors are becoming intrigued by the recent Diabetes ...read more
Promoter: OTCJournal Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $5,000 UNKNOWN
Max Profit: 1.05 % Gain at close: Pending
          If You Hate Disease and Love Money Then This Stock Is For You   Good evening!   My new pick aims to put a hault to the growing numbers of cancer and diabetes patients. Almost everyone knows somebody that has been impacted by one of these two diseases.   That's why companies like Merck and other pharmaceutical companies have flourished. They target problems that any person ...read more
Promoter: PENNY PICKS Paying Party: Cream Consulting
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $25,000 UNKNOWN
Max Profit: 5.05 % Gain at close: Pending
                PMCB Readies Diabetes Preclinical Study   Good Afternoon!   Type one (1) and two (2) diabetes is wreaking havoc across the world and in the US alone more than 29.1 million people are affected.   It is estimated that by 2017 the drugs treatment market for diabetes will be worth $55.3 billion. All this makes me very bullish about my latest short term ...read more
Promoter: Penny Stock Newsletters Paying Party: Cream Consulting
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $25,000 UNKNOWN
Max Profit: 5.05 % Gain at close: Pending
                PMCB Readies Diabetes Preclinical Study   Good Afternoon!   Type one (1) and two (2) diabetes is wreaking havoc across the world and in the US alone more than 29.1 million people are affected.   It is estimated that by 2017 the drugs treatment market for diabetes will be worth $55.3 billion. All this makes me very bullish ...read more
Promoter: BeatPennyStocks Paying Party: Cream Consulting
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $25,000 UNKNOWN
Max Profit: 5.05 % Gain at close: Pending
              PMCB Readies Diabetes Preclinical Study   Good Afternoon!   Type one (1) and two (2) diabetes is wreaking havoc across the world and in the US alone more than 29.1 million people are affected.   It is estimated that by 2017 the drugs treatment market for diabetes will be worth $55.3 billion. All this makes me very bullish about my latest short term ...read more
Promoter: Prepump Stocks Paying Party: Cream Consulting
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $25,000 UNKNOWN
Max Profit: 5.05 % Gain at close: Pending
                PMCB Readies Diabetes Preclinical Study   Good Afternoon!   Type one (1) and two (2) diabetes is wreaking havoc across the world and in the US alone more than 29.1 million people are affected.   It is estimated that by 2017 the drugs treatment market for diabetes will be worth $55.3 billion. All this makes me very bullish about my latest short term ...read more
Promoter: PennyStock Buzz Paying Party: Cream Consulting
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $25,000 UNKNOWN
Max Profit: 5.05 % Gain at close: Pending
                PMCB Readies Diabetes Preclinical Study   Good Afternoon!   Type one (1) and two (2) diabetes is wreaking havoc across the world and in the US alone more than 29.1 million people are affected.   It is estimated that by 2017 the drugs treatment market for diabetes will be worth $55.3 billion. All this makes me very bullish about my latest short term ...read more
Promoter: DAMN GOOD PENNY PICKS Paying Party: Cream Consulting
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $25,000 UNKNOWN
Max Profit: 5.05 % Gain at close: Pending
                      PMCB Readies Diabetes Preclinical Study   Good Afternoon!   Type one (1) and two (2) diabetes is wreaking havoc across the world and in the US alone more than 29.1 million people are affected.   It is estimated that by 2017 the drugs treatment market for diabetes will be worth $55.3 billion. All this makes me very bullish about ...read more
Promoter: PENNY PICKS Paying Party: Cream Consulting
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $25,000 UNKNOWN
Max Profit: 5.05 % Gain at close: Pending
Good Morning,   New Trade Alert: PharmaCyte Biotech, Inc. [ PMCB ] ‚Äč PMCB is my latest monster pick for a few main reasons: PMCB is rebounding from recent historical lows - providing us with massive upside at a discounted price - only 13 cents a share. In 2015 traded as high as 21 cents. Biotech has been one of the strongest performing sectors - PMCB is one of the few that is still potentially undervalued! PMCB ...read more
Promoter: HSP Team Paying Party: Cream Consulting
Stocks covered: Compensation: Avg $ Volume for Period:
PMCB $15,000 UNKNOWN
Max Profit: 8.52 % Gain at close: Pending
First  << 10  11  12  13  14  15  16  17  18  >> Last